

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)

EP 1 166 812 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
02.01.2002 Bulletin 2002/01

(51) Int Cl.⁷: **A61M 15/00**, **B65D 75/00**,
B65D 83/00, **B65B 11/00**,
B65D 73/00, **B29C 51/00**

(21) Application number: **01401722.2**

(22) Date of filing: **28.06.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **Microdose Technologies Inc.**
Monmouth Junction, NJ 08852 (US)

(72) Inventor: **Gumaste, Anand V.**
Robbinsville New Jersey 08691 (US)

(30) Priority: **28.06.2000 US 214578 P**

(74) Representative: **Audler, Philippe André et al**
Brevalex, 3, rue du Docteur Lancereaux
75008 Paris (FR)

(54) **Packaging and delivery of pharmaceuticals and drugs**

(57) A blister pack for use with inhalation therapy inhalers comprises an elongate bottom element 10 having

an overlying top element defining a plurality of spaced top crowned areas 14 containing powder or liquid medication or drugs.




FIG. 3

EP 1 166 812 A1

Description

[0001] The present invention relates generally to the field of metering, packaging and delivery of pharmaceuticals and drugs. Particular utility for the present invention is found in the area of facilitating metering and packaging of medications and drugs for inhalation therapy and will be described in connection with such utilities, although other utilities are contemplated, including liquid medication applications.

[0002] Certain diseases of the respiratory tract are known to respond to treatment by the direct application of therapeutic agents. As these agents are most readily available in dry powdered form, their application is most conveniently accomplished by inhaling the powdered material through the nose or mouth. This powdered form results in the better utilization of the medication in that the drug is deposited exactly at the site desired and where its action may be required; hence, very minute doses of the drug are often equally as efficacious as larger doses administered by other means, with a consequent marked reduction in the incidence of undesired side effects and medication cost. Alternatively, the drug in this form may be used for treatment of diseases other than those of the respiratory system. When the drug is deposited on the very large surface areas of the lungs, it may be very rapidly absorbed into the blood stream; hence, this method of application may take the place of administration by injection, tablet, or other conventional means.

[0003] It is the opinion of the pharmaceutical industry that the bioavailability of the drug is optimum when the drug particles delivered to the respiratory tract are between 1 to 5 microns in size. When the drug particles need to be in this size range the dry powder delivery system needs to address a number of issues:

(1) Small size particles develop an electrostatic charge on themselves during manufacturing and storage. This causes the particles to agglomerate or aggregate, resulting in clusters of particles which have an effective size greater than 5 microns. The probability of these large clusters making it to the deep lungs then decreases. This in turn results in a lower percentage of the packaged drug being available to the patient for absorption.

(2) The amount of active drug that needs to be delivered to the patient may be of the order of 10s of micrograms. For example, albuterol, in the case of a drug used in asthma, this is usually 25 to 50 micrograms. Current manufacturing equipment can effectively deliver aliquots of drugs in milligram dose range with acceptable accuracy. So the standard practice is to mix the active drug with a filler or bulking agent such as lactose. This additive also makes the drug "easy to flow". This filler is also called a carrier since the drug particles also stick to these particles through electrostatic or chemical

bonds. These carrier particles are very much larger than the drug particles in size. The ability of the dry powder inhaler to separate drug from the carrier is an important performance parameter in the effectiveness of the design.

(3) Active drug particles with sizes greater than 5 microns will be deposited either in the mouth or throat. This introduces another level of uncertainty since the bioavailability and absorption of the drug in these locations is different from the lungs. Dry powder inhalers need to minimize the drug deposited in these locations to reduce the uncertainty associated with the bioavailability of the drug.

[0004] Prior art dry powder inhalers (DPIs) usually have a means for introducing the drug (active drug plus carrier) into a high velocity air stream. The high velocity air-stream is used as the primary mechanism for breaking up the cluster of micronized particles or separating the drug particles from the carrier. Several inhalation devices useful for dispensing this powder form of medication are known in the prior art. For example, in U.S. Patent Nos. 3,507,277; 3,518,992; 3,635,219; 3,795,244; and 3,807,400, inhalation devices are disclosed having means for piercing or removing the top of a capsule containing a powdered medication, which upon inhalation is drawn out of the pierced or topped capsule and into the user's mouth. Several of these patents disclose propeller means, which upon inhalation aid in dispensing the powder out of the capsule, so that it is not necessary to rely solely on the inhaled air to suction powder from the capsule. For example, in U.S. Patent No. 2,517,482, a device is disclosed having a powder containing capsule placed in a lower chamber before inhalation, where it is pierced by manual depression of a piercing pin by the user. After piercing, inhalation is begun and the capsule is drawn into an upper chamber of the device where it moves about in all directions to cause a dispensing of powder through the pierced hole and into the inhaled air stream. U.S. Patent No. 3,831,606 discloses an inhalation device having multiple piercing pins, propeller means, and a self-contained power source for operating the propeller means via external manual manipulation, so that upon inhalation the propeller means aids in dispensing the powder into the stream of inhaled air. See also U.S. Patent No. 5,458,135.

[0005] These prior art devices present several problems and possess several disadvantages which are remedied by the inhalation devices of the present invention. For instance, these prior art devices require that the user exert considerable effort in inhalation to effect dispensing or withdrawal of powder from a pierced capsule into the inhaled air stream. With these prior art devices, suction of powder through the pierced holes in the capsule caused by inhalation generally does not withdraw all or even most of the powder out of the capsule, thus causing a waste of the medication. Also, such prior art devices may result in uncontrolled amounts or

clumps of powdered material being inhaled into the user's mouth, rather than a constant inhalation of controlled amounts of finely dispersed powder.

[0006] The above description of the prior art is taken largely from U.S. Pat. No. 3,948,264 to Wilke et al, who disclose a device for facilitating inhalation of a powdered medication that includes a body portion having primary and secondary air inlet channels and an outlet channel. The secondary inlet channel provides an enclosure for a capsule containing the powdered medication and the outlet channel is formed as a mouthpiece protruding from the body. A capsule piercing structure is provided, which upon activation forms one or more holes in the capsule so that upon vibration of the capsule by an electro-mechanical vibrator, the powdered drug may be released from the capsule. The piercing means disclosed in Wilke et al includes three radially mounted, spring-biased piercing needles mounted in a trochoidal chamber. Upon hand rotation of the chamber, simultaneous inward radial motion of the needles pierces the capsule. Further rotation of the chamber allows the needles to be retracted by their spring mountings to their original positions to withdraw the needles from the capsule. The electromechanical vibrator includes, at its innermost end, a vibrating plunger rod which projects into the intersection of the inlet channel and the outlet channel. Connected to the plunger rod is a mechanical solenoid buzzer for energizing the rod to vibrate. The buzzer is powered by a high energy electric cell and is activated by an external button switch. According to Wilke et al, upon inhalation through outlet channel 3 and concurrent pressing of switch 10d to activate the electromechanical vibrating means 10, air is sucked through inlet channels 4 and 12 and the air stream through the secondary inlet channel 4 raises the capsule up against the vibrating plunger rod 10a. The capsule is thus vibrated rapidly with powder being fluidized and dispensed from the pierced holes therein. (This technique is commonly used in manufacturing for dispensing powder through a hopper where the hopper is vibrated to fluidize the powder and move it through the hopper outlet. The pierced holes in the capsule represent the hopper outlet.) The air stream through inlet channel 4 and 12 aids in withdrawal of powder from the capsule and carries this powder through the outlet channel 3 to the mouth of the user. (Wilke et al, column 3, lines 45-55). Wilke et al further discloses that the electromechanical vibrator means may be placed at a right angle to the inlet chamber and that the amplitude and frequency of vibration may be altered to regulate dispensing characteristics of the inhaler.

[0007] Thus, as noted above, the vibrator in Wilke et al's disclosed inhaler is an electromechanical device consisting of a rod driven by a solenoid buzzer. (This electromechanical means may be a motor driving a cam [Col. 4, Line 40]). A disadvantage of the inhaler implementation as disclosed by Wilke is the relatively large mechanical movement required of the rod to effectively

vibrate the capsule. The large movement of the rod, usually around 100s of microns, is necessary due to the elasticity of the capsule walls and inertia of the drug and capsule.

5 [0008] Moreover, solenoid buzzers typically have operating frequencies less than 5 Khz. This operating frequency tends to be noisy and therefore is not desirable when incorporated into a dry powder inhaler from a patient's perspective. A further disadvantage of the electrochemical actuators of Wilke is the requirement for a high energy source (Wilke et al, Col. 3, line 38), thus requiring a large battery source or frequent changes of the battery pack for portable units. Both these features are not desirable from a patient safety and "ease of use" standpoint.

10 [0009] The inhaler of Wilke et al is primarily intended to reduce the amount of powder left behind in the capsule relative to other inhalers cited in the patent disclosure. (Wilke et al, Col. 4, lines 59-68, Col. 5, lines 1-48). However, Wilke et al does not address the need to deaggregate the powder into particle sizes or groups less than 5 microns in size as is required for effective delivery of the medication to the lungs; rather Wilke et al, like the prior art inhalers continues to rely on the air stream velocity to deaggregate the powder ejected into the air stream, into particle sizes suitable for delivery to the lungs.

15 [0010] Another prior art inhalation device is disclosed in Burns et al US. Patent No. 5,284,133. In this device, a liquid medication is atomized by an ultrasonic device such as a piezo element (Burns et al, Col. 10, lines 36-51). A stream of air, usually at a high velocity, or a propellant then carries the atomized particles to the patient. The energy required to atomize the liquid medication in the nebulizer is prohibitively high, making this approach for the delivery of drugs to the lungs only feasible as a desk top unit. The high voltage requirements to drive the piezo, to produce the necessary mechanical displacements, also severely affects the weight and size of the device. It is also not obvious that the nebulizer operating principles can be applied to the dry powder inhalers for delivery of powder medication to the lungs.

20 [0011] The prior art devices therefore have a number of disadvantages which makes them less than desirable for the delivery of dry powder to the lungs. Some of these disadvantages are:

- The performance of the prior art inhalers depends on the flow rate generated by the user. Lower flow rate does not result in the powder being totally deaggregated and hence adversely affects the dose delivered to the patient
- Inconsistency in the bioavailability of the drugs from dose-to-dose because of lack of consistency in the deaggregation process.
- Large energy requirements for driving the electro-mechanical based inhalers which increases the size of the devices making them unsuitable for port-

able use.

- Loss of medication from opened or topped capsules.
- Deterioration of medication in open or topped capsules due to exposure to oxygen or moisture.

[0012] In my prior U.S. Patent Nos. 6,026,809 and 6,142,146 (with Abrams), we provide an inhaler that utilizes vibration to facilitate suspension of a medication or drug into a gas that overcomes the aforesaid and other disadvantages and drawbacks of the above prior art. More particularly, the inhaler of our aforesaid patent includes a piezoelectric vibrator for vibrating the medication or drug. In a preferred embodiment of our aforesaid '809 and '146 patents, the medication or drug is supplied from a coiled tape having a plurality of spaced blisters or wells for carrying controlled aliquots of a dry powder medication or drug.

[0013] Referring to Fig. 1 which corresponds to Fig. 9 of our aforesaid '809 U.S. Patent, the medication or drug is packaged in a disposable drug cartridge 210 which includes a coiled tape 218 carrying a plurality of spaced flat walled blisters or wells 220 for containing controlled aliquots medication. A release film 221 covers and seals blisters or wells 220. Tape 218 is formed as a coil, and threaded between a first guide platen 222 and pinch roller 224. Pinch roller 224 in turn is driven by a take-up spool 226 which in turn is driven by a thumbwheel 228 which is mounted on a common shaft with the take-up spool 226. In use, release film 221 is peeled from the tape 218, whereby to open blisters or wells 220, one at a time, as the film is advanced through the cartridge, and the release film 221 is collected on take-up spool 226.

[0014] Completing cartridge 210 is a piezoelectric element 232 for mechanically engaging the bottom wall of the opened blisters or wells 220, one at a time, as they are selectively advanced in position over and in contact with the piezoelectric element 232. Tape 218 also preferably includes detent means or the like for indexing the tape so that a selected opened blister or well 220 is automatically positioned over piezoelectric element 232. Finally, an actuating circuit and power supply (not shown) is mounted within cartridge 210.

[0015] Preferably, but not necessarily, the interior walls of the housing are coated with a metallized coating 234 so as to obviate possible electrostatic charge build-up within the housing.

[0016] Also, if desired, an auxiliary air inlet 236 may be provided immediately upstream of the piezoelectric element 232 for assisting in carrying particles as they are energized by the piezoelectric element.

[0017] The present invention provides an improvement over the medication packaging and delivering technology described in our aforesaid '809 and '146 patents. More particularly, in accordance with the present invention, controlled aliquots or doses of a medication or drug are pre-packaged in a blister pack. The blister

pack includes a frangible crowned top element which may be conical, conical with a rounded point, rounded, or other raised shape configuration, and a bottom element which may be a flat web or membrane, or which itself may be of shaped configuration, e.g. conical, round, dish shaped, etc. for closely engaging with an underlying piezo element. The shape and size of the blisters is chosen to provide optimum controlled delivery of controlled amounts of controlled size particles of a given medication or drug. Before being delivered, the top element of the blister pack is pierced with a piercing device such as a sharp needle to form one or more apertures for delivery of the medication or drug contained within the blister pack. The hole pattern and hole size is selected to provide optimization of delivery of the particular medication or drug packaged therein. The holes also may act as filters whereby to prevent ejection from the blisters of aggregated or agglomerated particles, until the particles are broken up to optimal size by energy input from the piezo. Thus, in the case, e.g. of a dry powder medication or drug or a liquid medication or drug, particle size and dose of the medication or drug delivered can be optimized, and tailored to the frequency of the piezo. Typically, the bottom blister element is placed on/in close proximity to the piezo prior to or contemporaneously with piercing the top element. The top element is pierced, and activation of the piezo drives the medication or drug from the blister pack through the perforations in the top element.

[0018] Other features and advantages of the present invention will be seen from the following detailed description, taken in conjunction with the accompanying drawings, wherein:

Figs. 1a and 1b are schematic representations of a dry powder packaging and delivery system in accordance with the prior art;

Figs. 2 - 5 illustrate various blister packs made in accordance with the present invention; and

Figs. 6A and 6B illustrate a plurality of blister packs and piezos in accordance with another embodiment of the invention.

[0019] Referring to Fig. 2, a blister pack in accordance with the present invention comprises a bottom element 10 in the form of an elongate plastic tape or other flexible material, e.g. cloth, foil, paper, etc., having an overlying top element 12, carrying a plurality of spaced top crowned areas 14 containing controlled aliquots or doses of a dry powder medication or drug or a liquid medication or drug. As illustrated in Fig. 2, the top crowned areas 14 are shaped as inverted cones and are mounted to bottom element 10 in regular spaced intervals. Areas 14 are substantially completely filled with a controlled aliquot or dose of a powder or liquid medication or drug. Typically, the blister pack of the present invention is provided as coil or a circular cartridge or unit dose pack. In use, the blister pack is uncoiled and advanced to a punc-

ture stage where one or a plurality of controlled size holes 16 are punched through the top wall of the top crowned area 14.

[0020] The top crown areas 14 and bottom element 10 form an enclosed volume. The shape, height and volume of the blister pack, together with the size and number of holes punched through the top crowned area 14, play an important role in the de-aggregation and aerosolization of the powder or liquid material in the blister pack.

[0021] The three main phenomenon, besides others, which help in the de-aggregation and aerosolization of the material in the blister, are the Helm-Holtz resonator, the standing waves set-up in the blister pack and the vibrator frequency of the piezo. The Helm-Holtz resonator is formed by the holes punches in the top crown and the volume of the blister pack. The Helm-Holtz resonator helps to de-aggregate and eject the material from the blister pack. The frequency of the resonator will have to be optimized for maximum material de-aggregation and ejection efficiency.

[0022] The standing waves in the blister pack are determined by the height and shape of the blister. The standing waves help to lift and aerosolize the material in the blister. The standing wave frequency is determined by the height and shape of the blister pack and will have to be optimized for maximum de-aggregation of the material in the blister.

[0023] The third main phenomenon is the piezo vibrator frequency. The piezo frequency should be such as to excite the Helm-Holtz resonator and establish the standing waves in the blister pack. The interface of the element 10 with the piezo vibrator should be such as to provide maximum coupling of the piezo vibrator energy into the blister pack.

[0024] It will be appreciated by those skilled in the art that these three phenomenon need to be optimized individually or in combination to achieve maximum de-aggregation and aerosolization of the powder or liquid material in the blister pack to make it suitable for delivery of medication or other compounds to the lungs.

[0025] The tape is advanced so that that area 18 of the bottom portion underlying the punctured top crowned area 14 is in contact with or adjacent the piezoelectric element 20. The piezoelectric element 20 is then energized and couples with area 18, causing the blister pack to vibrate whereby to deaggregate and drive the powdered or liquid medication or drug out of the blister pack through holes 16.

[0026] Other shapes of blister packs made in accordance with the invention are shown in Figs. 3-5, and may include domed blister packs as illustrated in Fig. 3, dome/cone combinations as shown in Fig. 4, and cone/pill box combinations as shown in Fig. 5. In all cases the lower element should be flat or nearly flat or at least have a generally flattened or slightly rounded surface for interfacing or coupling with the piezo.

[0027] A particular feature and advantage of the

present invention is that the blister pack, when coupled to the piezo essentially acts as a miniature pump which expels the powder or liquid into the air stream.

[0028] The present invention offers several other advantages over the prior art. For one, the blister pack keeps the powdered or liquid medications or drugs freshly sealed and dry until just prior to use. Also, the blister pack keeps the powdered or liquid medications or drugs from flowing out or being lost, and allows the inhaler to be used in any orientation. Additionally, the size and shape of the top and bottom blister pack elements can be tuned to specific drug/piezo combinations for optimizing medication or drug delivery. Also, dosage size can be adjusted simply by changing the number of blister packs opened in the air channel. In such case, the multiple blisters may be opened simultaneously and driven by a common or by multiple piezos 20a, 20b ... (see Figs. 6A and 6B), or sequentially. Also, if desired, two or more piezos may be employed, e.g. adjacent the bottom and sides of the blisters, and activated simultaneously or sequentially. Another advantage as noted supra is that the holes in the blister pack serve as a filter or sieve so as to prevent expulsion from the blister pack of aggregated or oversize particles. Thus, overdosing and/or waste is eliminated.

[0029] Various changes may be made in the foregoing without departing from the spirit and scope of the invention. For example, the blister pack of the present invention advantageously may be employed for packaging and delivery of other wet or dry materials including, for example, vitamins, hormones, steroids and other bioactive small molecules, peptides, proteins, etc.

Claims

1. A blister pack for use with inhalation therapy inhalers comprising an elongate bottom element 10, having a frangible overlying top element 12 defining a plurality of spaced top crowned areas 14 containing powder or liquid material.
2. A blister pack according to claim 1, wherein said lower element 10 comprises an elongate flexible tape.
3. A blister pack according to claim 1 or 2, wherein said top crowned areas are shaped as inverted cones, or
4. A blister pack according to claims 1-3, wherein the bottom element 10 includes a depression 18 opposite the top crowned areas 14.
5. A blister pack according to claim 4, wherein the depression 18 is shaped as an inverted dome, or an inverted pill box.
6. A blister pack according to any of claims 1-5, where-

in said material comprises a medication, a vitamin, a hormone or a steroid.

7. A blister pack according to any of claims 1-5, wherein said material comprises a bioactive material. 5
8. A blister pack according to any of claims 1-7, wherein the size and number of holes together with volume formed by the blister pack are optimized for de-aggregation and aerosolization of material in the blister pack. 10
9. A blister pack according to any of claims 1-8, wherein the height and shape of the blister pack are optimized for de-aggregation and aerosolization of material in the blister pack. 15
10. A blister pack according to any of claims 1-9, wherein the interface to the vibrator is optimized for optimum coupling of the energy into the blister pack for de-aggregation and aerosolization of material in the blister pack. 20

25

30

35

40

45

50

55




FIG. 1a
PRIOR ART




FIG. 1b
PRIOR ART




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6a




FIG. 6b

European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 40 1722

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X, D	US 6 026 809 A (ABRAMS ANDREW L ET AL) 22 February 2000 (2000-02-22)	1, 2, 6-10	A61M15/00 B65D75/00 B65D83/00 B65B11/00 B65D73/00 B29C51/00
Y	* figure 9 *	3	
	* column 1, line 5-16 *		
	* column 3, line 16-46 *		
A	* column 8, line 29-65 *	4, 5	
Y	US 5 921 237 A (HOLTON NELSON ET AL) 13 July 1999 (1999-07-13)	3	
	* column 3, line 60 - column 4, line 6; figures 20, 22 *		
X	US 6 029 663 A (CAMERON ALLAN ET AL) 29 February 2000 (2000-02-29)	1, 2, 4, 8, 9	
A	* figures 5, 13, 16 *	3, 5-7	
	* column 1, line 48-52 *		
	* column 3, line 10-30 *		
	* column 3, line 66 - column 4, line 10 *		
	* column 4, line 18-20 *		
A	US 4 072 249 A (EKENSTAM BO THURESSON AF ET AL) 7 February 1978 (1978-02-07)	1-7	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
	* abstract; figures *		
A	GB 2 264 237 A (NEWELL ROBERT EDWARD) 25 August 1993 (1993-08-25)	1, 3	A61M B65D B65B B29C
	* figure 4 *		
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 10 October 2001	Examiner Lager, J
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 (04/02) (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 40 1722

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-10-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6026809	A	22-02-2000	CA 2243663 A1	31-07-1997
			EP 0879067 A2	25-11-1998
			JP 2000503866 T	04-04-2000
			WO 9726934 A2	31-07-1997
			US 5694920 A	09-12-1997
US 5921237	A	13-07-1999	US 5622166 A	22-04-1997
			AU 729272 B2	01-02-2001
			AU 3646697 A	10-02-1998
			BR 9710880 A	17-08-1999
			CZ 9900189 A3	12-05-1999
			EP 0925084 A1	30-06-1999
			HU 9903819 A2	28-03-2000
			JP 2001507949 T	19-06-2001
			NO 990272 A	22-03-1999
			WO 9803217 A1	29-01-1998
			AU 695051 B2	06-08-1998
			AU 5251096 A	18-11-1996
			BG 62921 B1	30-11-2000
			BG 101992 A	31-07-1998
			BR 9608194 A	21-07-1998
			CA 2217672 A1	31-10-1996
			CN 1181709 A	13-05-1998
			CZ 9703349 A3	14-01-1998
			EP 0835147 A1	15-04-1998
			HU 9801656 A2	28-10-1998
			IL 117706 A	30-11-1999
			JP 10512788 T	08-12-1998
			NO 974910 A	24-10-1997
			NZ 304654 A	28-01-1999
			PL 322909 A1	02-03-1998
			RO 115407 B1	28-02-2000
			SK 144697 A3	04-03-1998
			TW 384225 B	11-03-2000
			WO 9633759 A1	31-10-1996
			US 6029663 A	29-02-2000
US 6029663	A	29-02-2000	US 5622166 A	22-04-1997
			AU 695051 B2	06-08-1998
			AU 5251096 A	18-11-1996
			BG 62921 B1	30-11-2000
			BG 101992 A	31-07-1998
			BR 9608194 A	21-07-1998
			CA 2217672 A1	31-10-1996
			CN 1181709 A	13-05-1998
			CZ 9703349 A3	14-01-1998

EPC FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 40 1722

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-10-2001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6029663	A		EP 0835147 A1	15-04-1998
			HU 9801656 A2	28-10-1998
			IL 117706 A	30-11-1999
			JP 10512788 T	08-12-1998
			NO 974910 A	24-10-1997
			NZ 304654 A	28-01-1999
			PL 322909 A1	02-03-1998
			RO 115407 B1	28-02-2000
			SK 144697 A3	04-03-1998
			TW 384225 B	11-03-2000
			WO 9633759 A1	31-10-1996
			US 5921237 A	13-07-1999
US 4072249	A	07-02-1978	CA 1047459 A1	30-01-1979
			CH 605328 A5	29-09-1978
			DE 2608794 A1	16-09-1976
			DK 84076 A ,B,	04-09-1976
			FR 2302936 A1	01-10-1976
			GB 1539598 A	31-01-1979
			IN 145108 A1	26-08-1978
			JP 51143481 A	09-12-1976
			NL 7602203 A	07-09-1976
			SE 7502318 A	06-09-1976
			US 4282986 A	11-08-1981
GB 2264237	A	25-08-1993	NONE	

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82